<p>Merus (NASDAQ:MRUS - 获取免费报告) 的股票在周一由花旗集团的股票研究分析师重新给予了 “中性” 评级，Benzinga 报道。他们目前对这家生物技术公司的股票目标价为 97.00 美元，低于之前的 101.00 美元。花旗集团的目标价表明，相较于公司之前的收盘价，存在 40.80% 的潜在上涨空间。</p>
<p>其他几位股票分析师最近也对该股票进行了评论。华尔街禅在 7 月 20 日的研究报告中将 Merus 的股票评级从 “持有” 下调至 “卖出”。Alliance Global Partners 在 8 月 25 日的研究报告中开始覆盖 Merus 的股票。他们给予了该公司 “买入” 评级和 90.00 美元的目标价。HC Wainwright 在 8 月 6 日的研究报告中将 Merus 的股票评级上调至 “强力买入”。巴克莱在 9 月 17 日的报告中开始覆盖 Merus 的股票。他们设定了 “增持” 评级和 112.00 美元的目标价。最后，工业联盟证券在 8 月 25 日的报告中设定了 Merus 的 90.00 美元目标价。一位股票研究分析师给予该股票 “强力买入” 评级，十一位给予 “买入” 评级，一位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，共识目标价为 90.54 美元。</p>
<p><strong>查看我们关于 Merus 的最新研究报告</strong></p>
<h2>Merus 股票上涨 1.2%</h2>
<p>周一，Merus 股票开盘价为 68.89 美元。该公司的 50 日移动平均线为 66.53 美元，200 日移动平均线为 54.52 美元。Merus 的一年低点为 33.19 美元，一年高点为 70.65 美元。该公司的市值为 52.1 亿美元，市盈率为 -12.53，贝塔值为 1.19。</p>
<p>Merus (NASDAQ:MRUS - 获取免费报告) 最近在 8 月 5 日发布了季度财报。这家生物技术公司报告的每股收益为 -2.23 美元，低于分析师的共识预期 -1.17 美元，差距为 -1.06 美元。该公司季度收入为 883 万美元，而共识预期为 977 万美元。Merus 的股本回报率为 -50.28%，净利润率为 -685.64%。研究分析师预测，Merus 在本年度的每股收益将为 -3.85 美元。</p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席运营官 Peter B. Silverman 于 7 月 17 日出售了 25,000 股 Merus 股票。该股票以平均价格 60.00 美元出售，总价值为 1,500,000.00 美元。该交易已在提交给证券交易委员会的文件中披露，相关文件可通过 SEC 网站访问。在过去三个月中，内部人士共出售了价值 2,792,500 美元的 48,500 股公司股票。公司内部人士持有公司股票的 3.70%。</p>
<h2>机构投资者对 Merus 的看法</h2>
<p>几家大型投资者最近增加或减少了对 MRUS 的持股。Voya Investment Management LLC 在第一季度将其在 Merus 的持股增加了 26.3%。Voya Investment Management LLC 目前拥有 78,280 股这家生物技术公司的股票，价值 3,295,000 美元，此前在该期间内又购买了 16,280 股。US Bancorp DE 在第一季度将其在 Merus 的持股增加了 324.1%。US Bancorp DE 目前拥有 2,935 股这家生物技术公司的股票，价值 124,000 美元，此前在该期间内又购买了 2,243 股。Atle Fund Management AB 在第二季度将其在 Merus 的持股增加了 69.7%。Atle Fund Management AB 目前拥有 59,889 股这家生物技术公司的股票，价值 3,150,000 美元，此前在该期间内又购买了 24,597 股。GAMMA Investing LLC 在第一季度将其在 Merus 的持股增加了 2,153.6%。GAMMA Investing LLC 目前拥有 631 股这家生物技术公司的股票，价值 27,000 美元，此前在上个季度又购买了 603 股。最后，PNC Financial Services Group Inc. 在第一季度将其在 Merus 的持股增加了 30.0%。PNC Financial Services Group Inc. 目前拥有 5,800 股这家生物技术公司的股票，价值 244,000 美元，此前在该期间内又购买了 1,340 股。机构投资者和对冲基金持有公司 96.14% 的股票。</p>
<h2>Merus 公司简介</h2>
<p>(获取免费报告)</p>
<p>Merus N.V. 是一家临床阶段的免疫肿瘤学公司，专注于在荷兰开发抗体治疗。其双特异性抗体候选药物管线包括 Zenocutuzumab (MCLA-128)，该药物正在进行针对转移性乳腺癌和去势抵抗性前列腺癌患者的 2 期临床试验，同时也在进行针对携带 Neuregulin 1 的实体肿瘤的 1/2 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>SoundHound 突破关键阻力：现在能涨多高？</li>
<li>投资者如何识别并成功交易下跌股票</li>
<li>Klarna IPO：BNPL 股票还是更大的东西？</li>
<li>如何开始投资房地产</li>
<li>为什么 Teradyne 是 AI 硬件热潮中的核心投资</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
<p>在考虑 Merus 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Merus 并不在名单上。</p>
<p>虽然 Merus 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MRUS

<p>花旗集团重申了对 Merus（NASDAQ:MRUS）的 “中性” 评级，并将其目标价从 101.00 美元调整至 97.00 美元。这个目标价暗示相较于前一交易日收盘价有 40.80% 的潜在上涨空间。其他分析师的观点各异，其中一位将评级下调至 “卖出”，而其他则给予 “买入” 或 “强力买入” 评级。Merus 最近报告了每股亏损 2.23 美元，未能达到预期，市值为 52.1 亿美元。内部人士已出售股份，而机构投资者持有 96.14% 的股份</p>

<p>Merus (NASDAQ:MRUS - Get Free Report)'s stock had its &#34;neutral&#34; rating reissued by equities research analysts at Citigroup in a research note issued to investors on Monday,Benzinga reports. They currently have a $97.00 target price on the biotechnology company's stock, down from their prior target price of $101.00. Citigroup's price target indicates a potential upside of 40.80% from the company's previous close.</p>
<div class="lb-trans"><p>Merus (NASDAQ:MRUS - 获取免费报告) 的股票在周一由花旗集团的股票研究分析师重新给予了 “中性” 评级，Benzinga 报道。他们目前对这家生物技术公司的股票目标价为 97.00 美元，低于之前的 101.00 美元。花旗集团的目标价表明，相较于公司之前的收盘价，存在 40.80% 的潜在上涨空间。</p>
</div><p>Several other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of Merus from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Sunday, July 20th. Alliance Global Partners initiated coverage on shares of Merus in a research note on Monday, August 25th. They issued a &#34;buy&#34; rating and a $90.00 price objective for the company. HC Wainwright upgraded shares of Merus to a &#34;strong-buy&#34; rating in a research report on Wednesday, August 6th. Barclays initiated coverage on shares of Merus in a report on Wednesday, September 17th. They set an &#34;overweight&#34; rating and a $112.00 price target on the stock. Finally, Industrial Alliance Securities set a $90.00 price objective on Merus in a report on Monday, August 25th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Buy&#34; and a consensus target price of $90.54.</p>
<div class="lb-trans"><p>其他几位股票分析师最近也对该股票进行了评论。华尔街禅在 7 月 20 日的研究报告中将 Merus 的股票评级从 “持有” 下调至 “卖出”。Alliance Global Partners 在 8 月 25 日的研究报告中开始覆盖 Merus 的股票。他们给予了该公司 “买入” 评级和 90.00 美元的目标价。HC Wainwright 在 8 月 6 日的研究报告中将 Merus 的股票评级上调至 “强力买入”。巴克莱在 9 月 17 日的报告中开始覆盖 Merus 的股票。他们设定了 “增持” 评级和 112.00 美元的目标价。最后，工业联盟证券在 8 月 25 日的报告中设定了 Merus 的 90.00 美元目标价。一位股票研究分析师给予该股票 “强力买入” 评级，十一位给予 “买入” 评级，一位给予 “持有” 评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，共识目标价为 90.54 美元。</p>
</div><p><strong>Check Out Our Latest Research Report on Merus</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Merus 的最新研究报告</strong></p>
</div><h2>Merus Trading Up 1.2%</h2>
<div class="lb-trans"><h2>Merus 股票上涨 1.2%</h2>
</div><p>Shares of Merus stock opened at $68.89 on Monday. The company has a 50 day moving average of $66.53 and a 200-day moving average of $54.52. Merus has a 1-year low of $33.19 and a 1-year high of $70.65. The company has a market cap of $5.21 billion, a PE ratio of -12.53 and a beta of 1.19.</p>
<div class="lb-trans"><p>周一，Merus 股票开盘价为 68.89 美元。该公司的 50 日移动平均线为 66.53 美元，200 日移动平均线为 54.52 美元。Merus 的一年低点为 33.19 美元，一年高点为 70.65 美元。该公司的市值为 52.1 亿美元，市盈率为 -12.53，贝塔值为 1.19。</p>
</div><p>Merus (NASDAQ:MRUS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($1.06). The firm had revenue of $8.83 million for the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative return on equity of 50.28% and a negative net margin of 685.64%. Research analysts forecast that Merus will post -3.85 earnings per share for the current year.</p>
<div class="lb-trans"><p>Merus (NASDAQ:MRUS - 获取免费报告) 最近在 8 月 5 日发布了季度财报。这家生物技术公司报告的每股收益为 -2.23 美元，低于分析师的共识预期 -1.17 美元，差距为 -1.06 美元。该公司季度收入为 883 万美元，而共识预期为 977 万美元。Merus 的股本回报率为 -50.28%，净利润率为 -685.64%。研究分析师预测，Merus 在本年度的每股收益将为 -3.85 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, COO Peter B. Silverman sold 25,000 shares of Merus stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders sold 48,500 shares of company stock worth $2,792,500. Company insiders own 3.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席运营官 Peter B. Silverman 于 7 月 17 日出售了 25,000 股 Merus 股票。该股票以平均价格 60.00 美元出售，总价值为 1,500,000.00 美元。该交易已在提交给证券交易委员会的文件中披露，相关文件可通过 SEC 网站访问。在过去三个月中，内部人士共出售了价值 2,792,500 美元的 48,500 股公司股票。公司内部人士持有公司股票的 3.70%。</p>
</div><h2>Institutional Investors Weigh In On Merus</h2>
<div class="lb-trans"><h2>机构投资者对 Merus 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in MRUS. Voya Investment Management LLC lifted its stake in Merus by 26.3% in the first quarter. Voya Investment Management LLC now owns 78,280 shares of the biotechnology company's stock valued at $3,295,000 after buying an additional 16,280 shares during the period. US Bancorp DE grew its holdings in Merus by 324.1% in the first quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company's stock worth $124,000 after purchasing an additional 2,243 shares during the period. Atle Fund Management AB grew its holdings in Merus by 69.7% in the second quarter. Atle Fund Management AB now owns 59,889 shares of the biotechnology company's stock worth $3,150,000 after purchasing an additional 24,597 shares during the period. GAMMA Investing LLC increased its stake in Merus by 2,153.6% in the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after purchasing an additional 603 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in shares of Merus by 30.0% during the first quarter. PNC Financial Services Group Inc. now owns 5,800 shares of the biotechnology company's stock valued at $244,000 after purchasing an additional 1,340 shares during the period. Institutional investors and hedge funds own 96.14% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对 MRUS 的持股。Voya Investment Management LLC 在第一季度将其在 Merus 的持股增加了 26.3%。Voya Investment Management LLC 目前拥有 78,280 股这家生物技术公司的股票，价值 3,295,000 美元，此前在该期间内又购买了 16,280 股。US Bancorp DE 在第一季度将其在 Merus 的持股增加了 324.1%。US Bancorp DE 目前拥有 2,935 股这家生物技术公司的股票，价值 124,000 美元，此前在该期间内又购买了 2,243 股。Atle Fund Management AB 在第二季度将其在 Merus 的持股增加了 69.7%。Atle Fund Management AB 目前拥有 59,889 股这家生物技术公司的股票，价值 3,150,000 美元，此前在该期间内又购买了 24,597 股。GAMMA Investing LLC 在第一季度将其在 Merus 的持股增加了 2,153.6%。GAMMA Investing LLC 目前拥有 631 股这家生物技术公司的股票，价值 27,000 美元，此前在上个季度又购买了 603 股。最后，PNC Financial Services Group Inc. 在第一季度将其在 Merus 的持股增加了 30.0%。PNC Financial Services Group Inc. 目前拥有 5,800 股这家生物技术公司的股票，价值 244,000 美元，此前在该期间内又购买了 1,340 股。机构投资者和对冲基金持有公司 96.14% 的股票。</p>
</div><h2>Merus Company Profile</h2>
<div class="lb-trans"><h2>Merus 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.</p>
<div class="lb-trans"><p>Merus N.V. 是一家临床阶段的免疫肿瘤学公司，专注于在荷兰开发抗体治疗。其双特异性抗体候选药物管线包括 Zenocutuzumab (MCLA-128)，该药物正在进行针对转移性乳腺癌和去势抵抗性前列腺癌患者的 2 期临床试验，同时也在进行针对携带 Neuregulin 1 的实体肿瘤的 1/2 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>SoundHound Breaks Critical Resistance: How High Can It Get Now?</li>
<li>How Investors Can Identify and Successfully Trade Gap-Down Stocks</li>
<li>Klarna IPO: BNPL Stock or Something Bigger?</li>
<li>How to Start Investing in Real Estate</li>
<li>Why Teradyne Is a Core Play in the AI Hardware Boom</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Merus 更好</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>SoundHound 突破关键阻力：现在能涨多高？</li>
<li>投资者如何识别并成功交易下跌股票</li>
<li>Klarna IPO：BNPL 股票还是更大的东西？</li>
<li>如何开始投资房地产</li>
<li>为什么 Teradyne 是 AI 硬件热潮中的核心投资</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MRUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Merus 吗？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Merus 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Merus 并不在名单上。</p>
</div><p>While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merus 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Merus（纳斯达克代码：MRUS）被花旗集团给予中性评级